Skip to main content

Advertisement

Figure 9 | Molecular Cancer

Figure 9

From: Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival

Figure 9

Inhibition of HSP27 suppresses survival but does not alter sensitivity to temozolomide (TMZ) in primary glioma cell lines. A. Representative Western blots of HF373 and HF2303 cells treated with control siRNA (Csi) or HSP27 siRNA (HSP27si) for 72 hr. Equal numbers of siRNA-treated cells were plated overnight in growth serum and then treated with TMZ at the concentrations indicated for 2 days before lysing. Arrows indicate ≥ 2-fold increases or decreases due to siRNA treatment. # - Indicates a ≥ 2-fold increase in the ratio of LC-3II/LC-3I. Asterisks indicate ≥ 2-fold increases or decreases due to TMZ treatment. t = trend. B. Means for colony forming efficiency ± SD for HF373 and HF2303 cells ± HSP27 siRNA for 3000 cells/60-mm dish. HF373 * p = 0.0006; HF2303 * p = 0.017. C, D. Means for surviving fraction ± SD for HF373 and HF2303 cells treated with Control (Csi) or HSP27 (HSP27si) ± TMZ for 3000 cells/60-mm dish. Plating 1500 cells gave similar results.

Back to article page